|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 133 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Osteoarthritis Pain Overview
- Therapeutics Development
- An Overview of Pipeline Products for Osteoarthritis Pain
- Osteoarthritis Pain Therapeutics under Development by Companies
- Osteoarthritis Pain Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Osteoarthritis Pain Therapeutics – Products under Development by Companies
- Osteoarthritis Pain Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Osteoarthritis Pain Therapeutics Development
- Genzyme Corporation
- Johnson & Johnson
- Abbott Laboratories
- Allergan, Inc.
- Sanofi-Aventis
- Eli Lilly and Company
- BioDelivery Sciences International, Inc.
- Nektar Therapeutics
- MedImmune LLC
- Cephalon, Inc.
- Menarini Group
- BioChemics, Inc.
- Addex Pharmaceuticals
- Elite Pharmaceuticals, Inc.
- WhanIn Pharmaceutical Co., Ltd.
- Array BioPharma Inc.
- AnaMar Medical AB
- Neurotune AG
- IDEA AG
- QRxPharma Limited
- Iroko Pharmaceuticals, LLC
- Winston Pharmaceuticals, Inc.
- SantoSolve AS
- Antibe Therapeutics, Inc.
- Flexion Therapeutics
- Afferent Pharmaceuticals, Inc.
- Apimeds, Inc.
- Osteoarthritis Pain – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- CEP-33237 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ADX71943 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NT-11624 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ELI-216 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Vicodin CR - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Nucynta - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ABT-110 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ARRY-797 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BEMA Buprenorphine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Diractin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IP 045 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MoxDuo CR - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TASS - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GRT6005 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AF-219 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- JNJ-39439335 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Gen-S - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Apitoxin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Intra-Articular Civamide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Botox - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NKTR-181 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Botox - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SAR-292833 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ABT-652 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- 2PX - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Fasitibant - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MEDI-578 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Carbamazepine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- FX005 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GABA-BR PAM - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- THA902 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- FX006 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- FX007 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ibuprofen - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ATB-346 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug For Osteoarthritis Pain - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- WIN-34B - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Osteoarthritis Pain Therapeutics – Drug Profile Updates
- Osteoarthritis Pain Therapeutics – Discontinued Products
- Osteoarthritis Pain Therapeutics - Dormant Products
- Osteoarthritis Pain – Product Development Milestones
- Featured News & Press Releases
- Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta
- May 30, 2012: Flexion's FX005 Demonstrates Significant Prolonged Improvement In Pain And Function In Phase II Trial
- May 01, 2012: Endo Pharma Provides Supply Update On Voltaren Gel
- Aug 30, 2010: BioDelivery Sciences Reports BEMA Buprenorphine Phase II Study Results Selected For Presentation At Pain Week 2010
- Aug 30, 2010: J&JPRD And Grunenthal Report Phase III Study Data Comparing Tapentadol ER To Placebo In Patients With Chronic Osteoarthritis Knee Pain
- Aug 19, 2010: Lilly Reports Approval Recommendation From FDA Advisory Committee For Expanding Pain Indications For Cymbalta
- Jun 19, 2010: SantoSolve AS Present 2PX at EULAR congress
- Nov 17, 2009: SantoSolve Completes Patient Enrollment In First Pivotal Phase III Trial In Osteoarthritis
- Mar 12, 2009: Glenmark's GRC 15300 To Enter Phase I Trials
- Jan 24, 2009: Glenmark Pharma To Develop GRC 15300
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Osteoarthritis Pain, H2 2012
- Products under Development for Osteoarthritis Pain – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Investigation by Universities/Institutes, H2 2012
- Genzyme Corporation, H2 2012
- Johnson & Johnson, H2 2012
- Abbott Laboratories, H2 2012
- Allergan, Inc., H2 2012
- Sanofi-Aventis, H2 2012
- Eli Lilly and Company, H2 2012
- BioDelivery Sciences International, Inc., H2 2012
- Nektar Therapeutics, H2 2012
- MedImmune LLC, H2 2012
- Cephalon, Inc., H2 2012
- Menarini Group, H2 2012
- BioChemics, Inc., H2 2012
- Addex Pharmaceuticals, H2 2012
- Elite Pharmaceuticals, Inc., H2 2012
- WhanIn Pharmaceutical Co., Ltd., H2 2012
- Array BioPharma Inc., H2 2012
- AnaMar Medical AB, H2 2012
- Neurotune AG, H2 2012
- IDEA AG, H2 2012
- QRxPharma Limited, H2 2012
- Iroko Pharmaceuticals, LLC, H2 2012
- Winston Pharmaceuticals, Inc., H2 2012
- SantoSolve AS, H2 2012
- Antibe Therapeutics, Inc., H2 2012
- Flexion Therapeutics, H2 2012
- Afferent Pharmaceuticals, Inc., H2 2012
- Apimeds, Inc., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Osteoarthritis Pain Therapeutics – Drug Profile Updates
- Osteoarthritis Pain Therapeutics – Discontinued Products
- Osteoarthritis Pain Therapeutics – Discontinued Products (Contd..1)
- Osteoarthritis Pain Therapeutics – Dormant Products
- Osteoarthritis Pain Therapeutics – Dormant Products (Contd..1)
- List of Figures
- Number of Products under Development for Osteoarthritis Pain, H2 2012
- Products under Development for Osteoarthritis Pain – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractOsteoarthritis Pain – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Osteoarthritis Pain - Pipeline Review, H2 2012', provides an overview of the Osteoarthritis Pain therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. 'Osteoarthritis Pain - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Osteoarthritis Pain.
- A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Osteoarthritis Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
